Skip to content

SONNET BIOTHERAPEUTICS HOLDINGS, INC.: 10-Q filed 2024-05-14

What SONNET BIOTHERAPEUTICS HOLDINGS, INC. reported in its quarterly report filed 2024-05-14 (fiscal Q2 2024): 30 published measures, 86 facts as tagged in accession 0001493152-24-019264.

This filing

Form
10-Q (quarterly report)
Filed
2024-05-14
Fiscal period
fiscal Q2 2024
Accession
0001493152-24-019264 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SONNET BIOTHERAPEUTICS HOLDINGS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-03-315,909,409USD
At 2023-09-305,429,478USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-03-312,855,130USD
At 2023-09-305,655,458USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-03-313,054,279USD
At 2023-12-312,572,459USD
At 2023-09-30-225,980USD
At 2023-03-315,368,663USD
At 2022-12-31-3,537,232USD
At 2022-09-30-2,538,719USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-31365,425USD91
2023-10-01 to 2024-03-31-803,084USD183
2023-10-01 to 2023-12-31-1,168,509USD92
2023-01-01 to 2023-03-31-5,667,071USD90
2022-10-01 to 2023-03-31-11,209,213USD182
2022-10-01 to 2022-12-31-5,542,142USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-10-01 to 2024-03-31-2,367,945USD183
2022-10-01 to 2023-03-31-10,610,704USD182

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2023-10-01 to 2024-03-3118,626USD183
2023-01-01 to 2023-03-3136,445USD90
2022-10-01 to 2023-03-3173,700USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-10-01 to 2024-03-313,879,870USD183
2022-10-01 to 2023-03-3119,209,252USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2022-10-01 to 2023-03-31-261,250USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-03-31-111,046,837USD
At 2023-09-30-110,243,753USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-01-01 to 2024-03-314,617,665shares91
2023-10-01 to 2024-03-314,205,469shares183
2023-01-01 to 2023-03-31750,582shares90
2022-10-01 to 2023-03-31530,131shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-01-01 to 2024-03-314,885,845shares91
2023-10-01 to 2024-03-314,205,469shares183
2023-01-01 to 2023-03-31750,582shares90
2022-10-01 to 2023-03-31530,131shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-01-01 to 2024-03-310.08USD/shares91
2023-10-01 to 2024-03-31-0.19USD/shares183
2023-01-01 to 2023-03-31-7.55USD/shares90
2022-10-01 to 2023-03-31-21.14USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-01-01 to 2024-03-310.07USD/shares91
2023-10-01 to 2024-03-31-0.19USD/shares183
2023-01-01 to 2023-03-31-7.55USD/shares90
2022-10-01 to 2023-03-31-21.14USD/shares182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-03-3126,944USD
At 2023-09-3033,366USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-03-3160,395USD91
2023-10-01 to 2024-03-31110,400USD183
2023-01-01 to 2023-03-3156,998USD90
2022-10-01 to 2023-03-31148,615USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-03-31-3,868,561USD91
2023-10-01 to 2024-03-31-5,147,432USD183
2023-01-01 to 2023-03-31-5,664,768USD90
2022-10-01 to 2023-03-31-11,277,162USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-03-315,222,982USD
At 2023-09-304,738,229USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-03-312,764,684USD
At 2023-09-305,524,595USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-03-311,752,444USD
At 2023-09-302,201,999USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-01-01 to 2024-03-313,868,561USD91
2023-10-01 to 2024-03-315,166,058USD183
2023-01-01 to 2023-03-315,701,213USD90
2022-10-01 to 2023-03-3111,350,862USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-01-01 to 2024-03-312,167,288USD91
2023-10-01 to 2024-03-312,811,330USD183
2023-01-01 to 2023-03-313,816,644USD90
2022-10-01 to 2023-03-317,562,584USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-03-313,112,401shares
At 2023-09-301,750,426shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-03-31114,100,805USD
At 2023-09-30110,017,598USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-03-31159,641USD
At 2023-09-30193,689USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-03-31484,842USD
At 2023-09-30414,206USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-03-311,058,836USD
At 2023-09-301,677,396USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-01-01 to 2024-03-311,701,273USD91
2023-10-01 to 2024-03-312,354,728USD183
2023-01-01 to 2023-03-311,884,569USD90
2022-10-01 to 2023-03-313,788,278USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-10-01 to 2024-03-316,422USD183
2022-10-01 to 2023-03-316,422USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-10-01 to 2024-03-313,838,870USD183
2022-10-01 to 2023-03-3119,209,252USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2023-10-01 to 2024-03-31-368,681USD183
2022-10-01 to 2023-03-31-386,979USD182

Inspect the source

Entity
SONNET BIOTHERAPEUTICS HOLDINGS, INC. / CIK 0001106838
Captured
SEC response SHA-256
3f4ed3e191d870392f866d0b7de79fd0378ba4f8669f59d59de1a0b18cd3dce4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001106838.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))